M. Anne Szostak Net Worth

The estimated Net Worth of M Anne Szostak is at least $4.63 Million dollars as of 6 May 2024. Ms. Szostak owns over 257 units of Idexx Laboratories stock worth over $125,997 and over the last 22 years she sold IDXX stock worth over $4,193,677. In addition, she makes $312,482 as Independent Director at Idexx Laboratories.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Szostak IDXX stock SEC Form 4 insiders trading

M has made over 24 trades of the Idexx Laboratories stock since 2008, according to the Form 4 filled with the SEC. Most recently she sold 500 units of IDXX stock worth $234,685 on 5 September 2024.

The largest trade she's ever made was exercising 11,876 units of Idexx Laboratories stock on 4 February 2021 worth over $888,087. On average, M trades about 887 units every 66 days since 2003. As of 6 May 2024 she still owns at least 257 units of Idexx Laboratories stock.

You can see the complete history of Ms. Szostak stock trades at the bottom of the page.

M. Anne Szostak biography

M. Anne Szostak serves as Independent Director of the Company. Ms. Szostak had a 31-year career with Fleet/Boston Financial Group (now Bank of America), a diversified financial services company, until her retirement in 2004. She served as Chairman and Chief Executive Officer of Fleet Bank-Rhode Island from 2001 to 2003, Chairman, President and Chief Executive Officer of Fleet-Maine from 1991 to 1994, and Corporate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. After her retirement, Ms. Szostak founded Szostak Partners, an executive coaching and human resources consulting firm, and as President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School. Through her executive leadership roles at Fleet/Boston Financial Group, including serving as a chief executive officer of two major bank subsidiaries, Ms. Szostak brings extensive leadership, management, financial services and human resources experience to the Board. In particular, Ms. Szostak has deep expertise in human capital management, which is a key driver for our strategy of innovation. Ms. Szostak also leverages her substantial public company board experience, including in committee chair roles, in her service on our Board, including as Chair of the Compensation Committee.

What is the salary of M Szostak?

As the Independent Director of Idexx Laboratories, the total compensation of M Szostak at Idexx Laboratories is $312,482. There are 14 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.

How old is M Szostak?

M Szostak is 69, she's been the Independent Director of Idexx Laboratories since 2012. There are no older and 25 younger executives at Idexx Laboratories.

What's M Szostak's mailing address?

M's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.

Insiders trading at Idexx Laboratories

Over the last 21 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers, and Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.

What does Idexx Laboratories do?

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Complete history of Ms. Szostak stock trades at Idexx Laboratories, Tupperware Brands, and Keurig Dr Pepper Inc

Idexx Laboratories executives and stock owners

Idexx Laboratories executives and other stock owners filed with the SEC include:

• Jonathan Ayers,
  Director
• Jonathan Mazelsky,
  President, Chief Executive Officer, Director
• Brian McKeon,
  Chief Financial Officer, Executive Vice President, Treasurer
• Kathy Turner,
  Corporate Vice President and Chief Marketing Officer
• Jonathan J. Mazelsky,
  Pres, CEO & Director
• Sharon Underberg,
  Corporate Vice President, General Counsel, and Corporate Secretary
• Michael Lane,
  Executive Vice President, General Manager, Reference Laboratories and Information Technology
• Brian P. McKeon,
  CFO, Exec. VP & Treasurer
• Giovani Twigge,
  Chief Human Resource Officer, Corporate Vice President
• Dr. Nimrata Khatra Hunt P.E., Ph.D.,
  Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
• Michael J. Lane,
  Exec. VP and GM of Reference Laboratories & Information Technology
• James F. Polewaczyk,
  Exec. VP & Chief Commercial Officer
• Sharon E. Underberg,
  Exec. VP, Gen. Counsel, & Corp. Sec.
• Lawrence Kingsley,
  Independent Chairman of the Board
• M. Anne Szostak,
  Independent Director
• Daniel Junius,
  Independent Director
• Bruce Claflin,
  Independent Director
• Rebecca Henderson,
  Independent Director
• Sophie Vandebroek,
  Independent Director
• Stuart Essig,
  Independent Director
• Sam Samad,
  Independent Director
• Jonathan W. Ayers,
  Sr. Advisor & Director
• Asha Collins,
  Independent Director
• James Polewaczyk,
  Executive Vice President and Chief Commercial Officer
• Tina Hunt,
  Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations
• Dr. Martin Smith Ph.D.,
  Exec. VP & CTO
• Ken Grady,
  Sr. VP & Chief Information Officer
• Martin Smith,
  Exec. VP & CTO
• Jeffery D. Chadbourne,
  Sr. Director of Accounting & Financial Reporting
• John Hart,
  Sr. VP of Worldwide Operations
• Barry C Johnson,
  Director
• Thomas Craig,
  Director
• William End,
  Director
• Jacqueline Studer,
  CVP, Gen. Counsel & Secretary
• Thomas J Dupree,
  Corporate Vice President
• Michael J Williams,
  Corporate Vice President
• Daniel V Meyaard,
  Corporate Vice President
• Conan R Deady,
  Vice President and Secretary
• Joseph V Vumbacco,
  Director
• William E Iii Brown,
  Corporate Vice President
• William B. Goodspeed,
  Corporate Vice President
• Robert J Murray,
  Director
• Jeffrey Fiarman,
  EVP, GEN COUNSEL & SECRETARY
• Ali Naqui,
  Vice President
• Johnny D Powers,
  Corporate Vice President
• Errol B Desouza,
  Director
• William C Wallen,
  SVP & Chief Scientific Officer
• Quentin J Tonelli,
  Vice President
• S Sam Fratoni,
  Vice President
• Irene C Kerr,
  Corporate Vice President
• Robert S Hulsy,
  Vice President
• Laurel E Labauve,
  Vice President
• Merilee Raines,
  Vice President,CFO & Treasurer
• James L Jr Moody,
  Director
• Jennifer A Joiner,
  Corp VP CAG N American CommOps
• Louis W Pollock,
  Senior Vice President
• Erwin R Jr Workman,
  Executive Vice President
• Nimrata Hunt,
  Executive Vice President
• Irene Chang Britt,
  Director
• Martin Alexander Smith,
  Executive Vice President
• Michael Perkins Johnson,
  EVP and CHRO
• George Fennell,
  SVP, Chief Revenue Officer
• Michael G Erickson,
  Executive Vice President
• Michael Schreck,
  Executive Vice President